Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANTEPAR vs BILTRICIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
Praziquantel increases the permeability of cell membranes to calcium ions in susceptible schistosomes and other trematodes, causing sustained contraction and paralysis of the worm musculature, leading to detachment from blood vessel walls and eventual death.
Treatment of ascariasis (roundworm infection),Treatment of enterobiasis (pinworm infection)
Treatment of schistosomiasis (all species),Treatment of clonorchiasis sinensis (liver fluke),Treatment of opisthorchiasis (liver fluke),Off-label: Treatment of neurocysticercosis (in combination with corticosteroids),Off-label: Treatment of other trematode infections (e.g., fasciolopsiasis, intestinal flukes),Off-label: Treatment of cestode infections (e.g., diphyllobothriasis, taeniasis)
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
60 mg/kg/day orally in 3 divided doses (20 mg/kg/dose) for 1 day.
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is approximately 0.8-1.5 hours for praziquantel; clinical significance: short half-life necessitates multiple dosing for sustained antiparasitic effect.
Partially metabolized in the liver; some metabolites are excreted unchanged.
Extensively metabolized by the liver, primarily by cytochrome P450 enzymes (CYP3A4), to inactive hydroxylated metabolites.
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Renal excretion accounts for approximately 80-90% of elimination, primarily as metabolites; biliary/fecal excretion is minor (<10%).
Approximately 90% bound to plasma proteins, primarily albumin.
Approximately 80-85% bound to serum albumin.
Volume of distribution is approximately 0.6-1.0 L/kg, indicating distribution into total body water.
Volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution.
Oral bioavailability is approximately 80-90% due to extensive absorption with minimal first-pass metabolism.
Oral bioavailability is approximately 80% due to extensive first-pass metabolism; higher with food.
GFR 10-50 m L/min: administer 50-75% of normal dose; GFR <10 m L/min: administer 25-50% of normal dose; hemodialysis: administer after dialysis.
No dosage adjustment required for any degree of renal impairment.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 25-50%; Class C: contraindicated or use with extreme caution, reduce dose by 75%.
No specific Child-Pugh based adjustments; contraindicated in hepatocellular carcinoma or history of hepatic encephalopathy; use caution in severe liver disease.
Children: 10-20 mg/kg/day orally in 2 divided doses; maximum 750 mg/day for <10 kg, 1.5 g/day for 10-20 kg, 2.25 g/day for 20-40 kg, 3 g/day for >40 kg.
4 years and older: 60 mg/kg/day in 3 divided doses for 1 day; maximum single dose 2 g.
Elderly: initiate at lower end of dosing range; monitor renal function and adjust dose accordingly; avoid in patients with significant hepatic impairment.
No specific adjustments; use standard adult dosing with monitoring for adverse effects.
None.
None.
Caution in patients with epilepsy or impaired renal function; may cause neurotoxicity at high doses.
Avoid grapefruit juice during treatment due to increased praziquantel exposure.,May cause transient neurologic symptoms in patients with cerebral schistosomiasis or neurocysticercosis due to inflammatory reaction around dying parasites.,Use with caution in patients with hepatic impairment (Child-Pugh class B or C) as metabolism may be reduced.,May exacerbate cysticercosis if used without corticosteroids in neurocysticercosis.,Potential for cardiac arrhythmias in patients with ventricular arrhythmias or electrolyte disturbances (rare).
Hypersensitivity to piperazine; patients with pre-existing neurological disorders such as epilepsy.
Hypersensitivity to praziquantel or any component of the formulation,Ocular cysticercosis (due to risk of irreversible ocular damage from inflammatory response),Concurrent use with rifampin (significantly reduces praziquantel plasma concentrations),Children under 1 year of age (safety not established)
No significant food interactions reported. Avoid alcohol as it may increase CNS side effects. Take with food if gastrointestinal upset occurs.
Take with food to enhance bioavailability. Avoid grapefruit juice as it may increase drug levels. Alcohol may worsen CNS side effects and is not recommended.
ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. First trimester exposure may be associated with a slightly increased risk of congenital anomalies, though data are limited. Second and third trimester risks are not well-defined; use only if clearly needed.
Praziquantel (Biltricide) is FDA Pregnancy Category B. Animal studies show no teratogenic effects but embryotoxicity at high doses. Human data limited; no increased risk of major malformations reported. Avoid in first trimester unless essential; use in second/third trimester if benefit outweighs risk.
Piperazine is excreted into breast milk in small amounts. The M/P ratio is not established. The American Academy of Pediatrics considers piperazine compatible with breastfeeding, but caution is advised due to potential adverse effects in nursing infants. Use only if benefits outweigh risks.
Praziquantel is excreted into breast milk in small amounts; M/P ratio not established. After a single dose, milk levels low; consider pumping and discarding milk for 24-48 hours post-dose. Use with caution in nursing mothers.
No specific dose adjustments recommended during pregnancy. Piperazine pharmacokinetics may be altered due to increased plasma volume and renal clearance, but standard dosing is generally used. Monitor for efficacy and adverse effects.
No dose adjustment required for pregnancy; standard dosing (20 mg/kg three times daily for 1 day) unless hepatic impairment present. Pharmacokinetics in pregnancy not significantly altered; unchanged recommendations.
ANTEPAR (piperazine) is a first-line treatment for ascariasis and enterobiasis. It causes neuromuscular paralysis in worms via GABA receptor agonism. Contraindicated in epilepsy and renal impairment. Monitor for neurotoxicity (ataxia, confusion) especially in children. Effective against both adult and immature worms; no need for laxatives.
Administer with food to increase absorption and reduce GI side effects. Use with caution in hepatic impairment; dose adjustment may be necessary. Monitor for neuropsychiatric effects (e.g., dizziness, headache) especially in patients with CNS involvement of schistosomiasis. Avoid in patients with ocular cysticercosis due to risk of intraocular inflammation; treat ocular lesions first with corticosteroids.
Take exactly as prescribed; complete full course even if symptoms improve.,May cause dizziness or blurred vision; avoid driving until you know how the drug affects you.,Report any muscle weakness, tremors, or confusion to your doctor immediately.,For pinworm infection, all household members should be treated to prevent reinfection.,Practice strict hand hygiene and wash bed linens in hot water to reduce spread.
Take this medication with a meal to improve absorption and reduce stomach upset.,Do not chew or crush the tablets; swallow them whole.,Complete the full course of treatment even if you feel better.,You may experience dizziness, drowsiness, or headache; avoid driving or operating heavy machinery until you know how the drug affects you.,Inform your doctor if you have liver disease or are taking other medications.,Contact your doctor if you experience severe headache, seizures, or vision changes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANTEPAR vs BILTRICIDE, answered by our medical review team.
ANTEPAR is a Anthelmintic that works by Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.. BILTRICIDE is a Anthelmintic that works by Praziquantel increases the permeability of cell membranes to calcium ions in susceptible schistosomes and other trematodes, causing sustained contraction and paralysis of the worm musculature, leading to detachment from blood vessel walls and eventual death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANTEPAR and BILTRICIDE depend on the specific clinical indication. These are both Anthelmintic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANTEPAR is: Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.. The standard adult dose of BILTRICIDE is: 60 mg/kg/day orally in 3 divided doses (20 mg/kg/dose) for 1 day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANTEPAR and BILTRICIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANTEPAR is classified as Category C. ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. Fir. BILTRICIDE is classified as Category C. Praziquantel (Biltricide) is FDA Pregnancy Category B. Animal studies show no teratogenic effects but embryotoxicity at high doses. Human data limited; no increased risk of major m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.